Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rottlerin is a natural polyphenolic compound isolated from the fruit of *Mallotus philippinensis* (the Kamala tree). It is widely utilized in biochemical research as a pharmacological tool. Historically, rottlerin was identified as a selective inhibitor of Protein Kinase C delta (PKCδ), although subsequent studies have demonstrated that it also acts as a mitochondrial uncoupler, which in turn activates AMPK and inhibits the PI3K/Akt/mTOR signaling pathway. In oncology research, rottlerin has been shown to induce autophagy and apoptosis in various cancer cell lines, including prostate cancer stem cells, by modulating these pathways. Beyond its research applications, rottlerin has traditional uses in Ayurvedic medicine for its anti-allergic and anti-helminthic properties.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on rottlerin.